Duke-NUS spinout PairX Bio launches with strong biotech credentials, VC backing

(Duke-NUS Medical School) Duke-NUS spinout company, PairX, led by seasoned US and Singapore scientists and financiers with strong track records in biotech startups, venture capital and investment, aims to advance innovative biotechnology built on deep expertise in mRNA splicing biology and a proprietary immunotherapy platform exclusively licensed from Duke-NUS Medical School.